Assessment Status |
Rapid Review Complete |
HTA ID |
25014 |
Drug |
Tislelizumab |
Brand |
Tevimbra® |
Indication |
Tislelizumab (Tevimbra®) as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy. |
Rapid review commissioned |
18/02/2025 |
Rapid review completed |
04/03/2025 |
Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tislelizumab compared with the current standard of care. |